RUSH System for CAR-T Cells

Scale or prepare manufacturing, process control, GMP readiness and quality workflows.

Scientific visual associated with RUSH System for CAR-T Cells
Bioproduction expertise — Curie Cancer
01Carnot instituteCurie Cancer
02Development stageCMC / process / GMP readiness
03Main expertiseBioproduction
04Relevant fieldsOncology

Offer overview

What this offer helps you achieve

Scale or prepare manufacturing, process control, GMP readiness and quality workflows.

Scientific and technical scope

Our CAR-T cell technology, CARTuneTM, addresses the high toxicity in CAR-T therapies while maintening their efficiency. Based on our proprietary "traffic switch" platform and the RUSH system, it controls CAR protein expression using Biotin, a non-toxic molecule. This innovation enhances efficacy and reduces toxicity, making it suitable for both Leukemia and solid tumors, and allowing for versatile, off-the-shelf treatment options.
01

Capabilities mobilised

Therapeutic areasFormulation and synthesisValidation using preclinical modelsBioproductionPlatforms
02

Application fields

Oncology

Discuss this offer

Could this capability strengthen your R&D programme?

Present your scientific, technical or clinical need and identify the most relevant route to collaboration.